Sugi Predict

Sugi Predict / Compounds / SCHEMBL718872

SCHEMBL718872

SCHEMBL718872

CC(=O)OC[C@H]1O[C@@H](Oc2nn(C(C)C)c(C)c2Cc2ccc(OC(C)C)cc2)[C@H](O)[C@@H](O)[C@@H]1O

nearest known ligand 0.85

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ SLC5A2 P31639 20/20 0.85
▸ SLC5A1 P13866 18/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL877233 0.94 SLC5A2 (0.95) SLC5A2SLC5A1
SCHEMBL14634764 0.94 SLC5A2 (0.95) SLC5A2SLC5A1
SCHEMBL14634761 0.94 SLC5A2 (0.95) SLC5A2SLC5A1
SCHEMBL14634762 0.93 SLC5A2 (0.85) SLC5A2SLC5A1
SCHEMBL2253384 0.93 SLC5A2 (0.89) SLC5A2SLC5A1
Remogliflozin Etabonate SCHEMBL23072082 0.92 SLC5A2 (1.00) SLC5A2SLC5A1
Remogliflozin Etabonate SCHEMBL15168697 0.92 SLC5A2 (1.00) SLC5A2SLC5A1
Remogliflozin Etabonate SCHEMBL18432846 0.92 SLC5A2 (1.00) SLC5A2SLC5A1
Remogliflozin Etabonate SCHEMBL17034638 0.92 SLC5A2 (1.00) SLC5A2SLC5A1
SCHEMBL2253492 0.92 SLC5A2 (0.85) SLC5A2SLC5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140371162-A1 COMBINATION THERAPY COMPRISING SGLT INHIBITORS AND DPP4 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2014-12-18 — — US disclosed
US-8853385-B2 Combination therapy comprising SGLT inhibitors and DPP4 inhibitors MITSUBISHI TANABE PHARMA CORPORATION (JP) 2014-10-07 — — US disclosed
US-20120053330-A1 Chemical Process GLAXOSMITHKLINE LLC 2012-03-01 — — US disclosed
US-20120053330-A1 Chemical Process GLAXOSMITHKLINE LLC 2012-03-01 — — US disclosed
US-20120053330-A1 Chemical Process GLAXOSMITHKLINE LLC 2012-03-01 — — US disclosed
US-7989424-B2 Glucopyranosyloxypyrazole derivatives and use thereof in medicines KISSEI PHARMACEUTICAL CO., LTD. (JP) 2011-08-02 — — US disclosed
US-20110059912-A1 COMBINATION THERAPY COMPRISING SGLT INHIBITORS AND DPP4 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-03-10 — — US disclosed
EP-1354888-B1 GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES KISSEI PHARMACEUTICAL (JP) 2009-05-20 — — EP disclosed
US-20090093419-A1 GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES KISSEI PHARMACEUTICAL CO. LTD. (JP) 2009-04-09 — — US disclosed
US-7465713-B2 Glucopyranosyloxypyrazole derivatives and use thereof in medicines KISSEI PHARMACEUTICAL CO., LTD. (JP) 2008-12-16 — — US disclosed
US-7429568-B2 Antidiabetic agents; human SGLT2 (sodium ion / glucose cotransporter 2) inhibitors; hyperglycemia, obesity; 3-(6-O-ethoxycarbonyl- beta -D-glucopyranosyloxy)-4-[(4-isopropoxyphenyl)methyl]-1-isopropyl-5-methylpyrazole KISSEI PHARMACEUTICAL CO., LTD. (JP) 2008-09-30 — — US disclosed
US-7393838-B2 Glucopyranosyloxypyrazole derivatives and use thereof in medicines KISSEI PHARMACEUTICAL CO., LTD. (JP) 2008-07-01 — — US disclosed
US-7084123-B2 Glucopyranosyloxypyrazole derivatives and use thereof in medicines KISSEI PHARMACEUTICAL CO., LTD. (JP) 2006-08-01 — — US disclosed
US-20060094667-A1 Glucopyranosyloxypyrazole derivatives and use thereof in medicines KISSEI PHARMACEUTICAL CO., LTD. 2006-05-04 — — US disclosed
US-20060035847-A1 Glucopyranosyloxyprazole derivatives and use thereof in medicines KISSEI PHARMACEUTICAL CO., LTD. 2006-02-16 — — US disclosed
US-20060025352-A1 Glucopyranosyloxypyrazole derivatives and use thereof in medicines Kissei Pharmaceutical Co.,Ltd. 2006-02-02 — — US disclosed
US-20040063646-A1 Glucopyranosyloxypyrazole derivatives and use thereof in medicines KISSEI PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 — — US disclosed
EP-1354888-A1 GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES Kissei Pharmaceutical Co., Ltd. (JP) 2003-10-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053330-A1 Chemical Process SLC5A2, SLC5A1, UGGT1 SLC5A2 1/4885SLC5A1 2/4885
US-20140371162-A1 COMBINATION THERAPY COMPRISING SGLT INHIBITORS AND DPP4 INHIBITORS DPP4, SLC5A1, GLP1R SLC5A2 5/4885SLC5A1 2/4885
US-20090093419-A1 GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES SLC5A2, SLC5A1, SLC2A4 SLC5A2 1/4885SLC5A1 2/4885
US-20110059912-A1 COMBINATION THERAPY COMPRISING SGLT INHIBITORS AND DPP4 INHIBITORS DPP4, SLC5A1, GLP1R SLC5A2 5/4885SLC5A1 2/4885
US-20060035847-A1 Glucopyranosyloxyprazole derivatives and use thereof in medicines SLC5A2, SLC5A1, SLC2A4 SLC5A2 1/4885SLC5A1 2/4885
US-20060094667-A1 Glucopyranosyloxypyrazole derivatives and use thereof in medicines SLC5A2, SLC5A1, SLC2A2 SLC5A2 1/4885SLC5A1 2/4885
US-20040063646-A1 Glucopyranosyloxypyrazole derivatives and use thereof in medicines SLC5A2, SLC5A1, UGGT1 SLC5A2 1/4885SLC5A1 2/4885
US-20060025352-A1 Glucopyranosyloxypyrazole derivatives and use thereof in medicines SLC5A2, SLC5A1, SLC2A2 SLC5A2 1/4885SLC5A1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.